No Conflict of Interest
|
|
- Alexandra Harrington
- 5 years ago
- Views:
Transcription
1
2 No Conflict of Interest
3 Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine
4 Objectives Understand the aging of the Immune System in the HIV population and how it relates to development of Co-morbidities Discuss the Epidemiology of HIV in the aging population Discuss the Challenges in: HIV diagnosis HIV care Management of Co-morbidities
5 AGING: Britanica Encyclopedia Gradual change in an organism that leads to increased risk of weakness, disease, and death. It takes place in a cell, an organ, or the total organism over the entire adult life span of any living thing... Changes in organs include the replacement of functional cardiovascular cells with fibrous tissue. Overall effects of aging include reduced immunity, loss of muscle strength, decline in memory and other aspects of cognition, and loss of colour in the hair and elasticity in the skin. In women, the process accelerates after menopause.
6 How old is aging in HIV?
7 Aging and Comorbidities Common disorders in older adults Cardiovascular disease Hypertension Metabolic disorders, obesity Neurocognitive decline Hepatic and/or renal impairment Bone fractures/osteopenia/osteoporosis Malignancies
8 The process of aging in HIV Aging HIV Aging related Co-morbidities HTN, DM, CVD, cancers, cognitive decline Mechanisms Persistent immune activation Immune senescence Microbial translocation Chronic inflammation Telomere length Telomerase activity
9 Aging HIV State of immune activation, immune senescence, microbial translocation, inflammation Biomarkers of cardiovascular disease in HIV infected postmenopausal women on ART
10 HIV infected post-menopausal women HIV n=15 HIV+ n=27 P value Age (years) 59 (53 63) 56.5 (48 66).11 Time to menopause (years) 15 (3 29) 12 (2 22).9 CD4 cell count (cells/mm 3 ) n.a. 584 (144 1,144) CD4 nadir (cells/mm 3 ) n.a. 147 (2 648) HIV RNA (copies/ml) n.a. undetectable 8 Current smoking 13% 8%.61 Current illicit drug use 6% 4% 1. Body mass index (kg/m 2 ) 31.4 ( ) 27.6 ( ).2 Alcaide et al. PLOS ONE 213
11 Tcell cellular markers of IA HIV HIV+ P value T cell activation CD38+ HLA-DR+ CD4 (%) 1.69± ± CD38+ HLA-DR+ CD8 (%) 2.8± ±13.26 <.1 Ki-67+ CD4 (%).39±.22.63± Ki-67+ CD8 (%).32±.9.34± T cell exhaustion PD-1+ CD4 (%) 13.36± ± PD-1+ CD8 (%) 16.72± ± T cell senescence CD28 CD57+ CD4 (%) 2.22± ± CD28 CD57+ CD8 (%) 16.7± ± Alcaide et al. PLOS ONE 213
12 Soluble markers of IA and MT HIV HIV+ P value Monocyte/macrophage activation scd14 (ng/ml) 1,537±253 2,113±426 <.1 scd163 (ng/ml) 323± ±26.43 T cell activation scd25 (ng/ml) 387.3± ± Microbial translocation LPS (pg/ml) 9.2± ± Alcaide et al. PLOS ONE 213
13 Inflammatory Cytokines HIV HIV+ P value IL-6 (pg/ml).89± ± IL-8 (pg/ml) 4.38± ± IL-1 (pg/ml) 3.31± ± TNFα (pg/ml) 7.2± ± Alcaide et al. PLOS ONE 213
14 Tcell immune activation Tcell exhaustion Tcell senescence Microbial Translocation Soluble markers of IA Inflammatory Cytokines Alcaide et al. PLOS ONE
15 IA and senescence are associated with low CD4 FI in cells % CD28 CD57+ CD8 T cells % CD38+ HLA-DR+ CD8 T cells % PD-1+ CD8 T cells FI in ells % CD28 CD57+ CD8 T cells % CD38+ HLA-DR+ CD8 T cells % PD-1+ CD8 T cells FI in cells % CD28 CD57+ CD8 T cells % CD38+ HLA-DR+ CD8 T cells % PD-1+ CD8 T cells % CD28 CD57+ CD8 T cells % CD38+ HLA-DR+ CD8 T cells % PD-1+ CD8 T cells % CD28 CD57+ CD8 T cells % CD38+ HLA-DR+ CD8 T cells % PD-1+ CD8 T cells FI in cells % CD28 CD57+ CD4 T cells % PD-1+ CD4 T cells FI in ells % CD38+ HLA-DR+ CD4 T cells % CD28 CD57+ CD4 T cells % PD-1+ CD4 T cells % CD38+ HLA-DR+ CD4 T cells FI in cells % CD28 CD57+ CD4 T cells % PD-1+ CD4 T cells % CD38+ HLA-DR+ CD4 T cells % CD28 CD57+ CD4 T cells % PD-1+ CD4 T cells % CD38+ HLA-DR+ % CD38+ CD4 T HLA-DR+ cells CD4 T cells % CD28 CD57+ CD4 T cells % PD-1+ CD4 T cells %CD38+HLA-DR+ CD8 Tcells/CD4 A A B B C C D D R = p = R.315 = p = , 1,5 1, 1,5 5 1, 1,5 5 1, 1,5 5 21, 1,5 CD4 T cell count (cells/mm , 1,5 CD4 ) T CD4 T cell count (cells/mm 3 ) CD4 T cell count (cells/mm 3 cell count (cells/mm ) 3 ) 2CD4 2 CD4 T cell count (cells/mm 3 T cell count (cells/mm ) 3 ) %PD-1+ CD8 Tcells/CD , 1, 1,5 1, , 1,5 5 B R = R = R = R = p = R.256 CD4 = T cell CD4 count T cell (cells/mm count (cells/mm p = R.1667 = p = ) 3 ) CD4 CD4 T T cell cell count count p (cells/mm 3 =.1667 ) 4 4 p =.256 p = B 5 R = R = B 5 R = p =.256 R p = p 2 = p = , 1,5 5 1, 1,5 5 1, 1,5 1, 1,5 5 1, 2 2 1,5 5 1, 1,5 CD4 T cell count (cells/mm 3 1 ) CD4 T cell count (cells/mm 3 ) CD4 T cell count (cells/mm CD4 T 3 ) cell count (cells/mm 3 2 ) CD4 T cell count (cells/mm CD4 3 ) T cell count (cells/mm 3 ) 1 5 1, 1,5 5 1, 1,5 8 R = C 8 5 CD4 T cell count 1, (cells/mm 1,5 3 ) 5 5 R = CD4 5 T cell count 1, (cells/mm 3 ) 1,5 R = -.97 R = -.97 R = R = p =.672 p =.25 p CD4 =.672 T cell count (cells/mm p = ) p =.25 p = CD4 T cell count (cells/mm 3 ) 6 6 %CD28-CD57+ CD4 Tcells/CD4 C 8 3 R = R = p =.672 p = C R 2 = R = p =.672 p = , 1,5 1,5 1, 1, , 1, 1 1,5 1,5 1, 1,5 CD4 CD4 T cell T cell count count (cells/mm (cells/mm CD4 3 ) T 3 ) cell count (cells/mm 3 2 ) CD4 CD4 T cell T cell count count (cells/mm (cells/mm CD4 3 ) 3 ) T cell count (cells/mm 3 ) 2 5 1, 1, , 1,5 CD4 T cell count (cells/mm 3 ) CD4 T cell count (cells/mm 3 ) 4, 4, D 4, 5, 5 1,5, 1,5 5, 5 1, 1,5 3, 3, A A A R = p = R = p =.315 4R = p = , %CD38+HLA-DR+ CD4 Tcells/CD4 8 R = p = R.131 = p = R = p =.131 4, 3, D 4, CD4 T cell count (cells/mm 4, 3 ) 4, 5, CD4 T cell count (cells/mm 3 ) %PD-1+ CD4 Tcells/CD4 R = p R = p =.131
16 Biomarkers of CVD HIV HIV+ P value Cardiovascular disease svcam-1 (ng/ml) 287.± ± sicam-1 (ng/ml) 1.4± ± Alcaide et al. PLOS ONE
17 svcam-1 (ng/ml) sicam-1 (ng/ml) CXCL1 (pg/ml) svcam-1 (ng/ml) sicam-1 (ng/ml) CXCL1 (pg/ml) svcam-1 (ng/ml) sicam-1 (ng/ml) CXCL1 (pg/ml) svcam-1 (ng/ml) sicam-1 (ng/ml) CXCL1 (pg/ml) svcam-1 (ng/ml) sicam-1 (ng/ml) CXCL1 (pg/ml) A ,5 4 3 Biomarkers of CVD 2 are associated 1, 4with the state Linear of regression: immune 2 2 all donors activation and with low CD4 counts R = HIV+ 5 1, 1,5 2, 2,5 scd25 (ng/ml) R =.4682 p = R =.6179 p <.1 5 1, 1,5 2, 2,5 scd25 (ng/ml) C 2,5 2, 8 6 R = -.25 p =.9874 p =.1 5 1, 1,5 2, 2, scd25 (ng/ml) 2 25 TNFa (pg/ml) Donors: HIV 5 HIV+ 4 R =.5851 p = TNFa (pg/ml) B svcam / scd R =.4219 p = sicam / scd14 R =.4883 p =.14 D 2,5 2, 1,5 1, 5 svcam / CD4 count 8 R =.3319 p = R = p =.471 sicam / CD4 count R = p =.839 1, 2, 3, 4, scd14 (ng/ml) 1, 2, 3, 4, scd14 (ng/ml) 1, 5 2, 3, 1, 4, 1,5 CD4 scd14 T cell (ng/ml) count (cells/mm 3 ) 5 1, 1,5 CD4 T cell count (cells/mm 3 ) C R =.5851 p =.1 2,5 2, R =.2658 p = ,5 1, 2 R =.5822 p = TNFa (pg/ml) TNFa (pg/ml) TNFa (pg/ml) D 8 R = R = ,5 R = Alcaide et al. PLOS ONE
18 HIV infected post-menopausal women Aging HIV Despite appropriate immunological and virological response to ART: - The immune system of HIV infected aging women is in a higher state immune activation - The state of IA predispose them to develop CVD IA and risk for CVD are associated with lower CD4 counts
19 Epidemiology of HIV in the aging population
20 Persons Living With HIV (%) People living with HIV Over one third of individuals with HIV are older than 5 years 52.7% 5.7% 48.6% % 3.6% 32.7% % 17.1% 17.3% 1 1.6% 1.6% 1.4% < (n=733,49) (n=76,347) (n=784,71) 6-64 >65 Years <2 35 to 49 CDC. HIV Surveillance Report, to 34 >5
21 By 215, approximately 5% of people living with HIV will be older than 5 years of age. NIH statement on National HIV/AIDS and Aging Awareness Day Sept. 18, 21. Available at:
22 Concurrent HIV/AIDS CDC. HIV Surveillance Report, 26.
23 New HIV diagnosis < >5 CDC. HIV Surveillance Report,
24 Challenges in HIV diagnosis, HIV care and management of Co-morbidities in the aging population
25 CHALLENGES IN DIAGNOSIS 63 yo male DM HTN Married for 3 years Diagnosed with HIV infection during labs done as part of a DM research study CD4=537, VL=9,
26 Challenges in HIV diagnosis Routine voluntary testing for patients ages 13 to 64 years in healthcare settings
27 Challenges in HIV diagnosis 29 National Health Interview Survey (NHIS) 12,366 adults over 5 years 75% had never been tested for HIV 84% thought they had no chances of getting HIV The most common reason for testing was patient request No difference in testing rates by race
28 Late or Missed Diagnosis in Older Adults Poor awareness of HIV risk factors (including safe sex practices) Lack of HIV prevention education targeting older adults Health care provider belief that older adults are not sexually active Failure of some health care providers to consider HIV infection in this patient population Luther VP, et al. Clin Geriatr Med. 27;23: Illa L, et al. AIDS Behav. 28;12:
29 Challenges in HIV diagnosis Sexual risk behaviors among 624 men over 5 years In the prior 6 months: 75% sexually active (48% weekly or more) 5% drug use 18% use condoms 24% more than one sex partner
30 CHALLENGES IN HIV CARE 6 yo female HIV 23 years Nadir CD4=23 CD4=13, RNA<2 Cervical cancer HTN Unable to achieve CD>2 despite adherence to medication
31 HIV RNA (log 1 copies/ml) CD4 (cells/mm 3 ) 5.3 Baseline viral load and CD4 counts Baseline HIV RNA Baseline CD4 Count > >6 Age (years) Age at Baseline (years) Lower CD4 counts and higher VL at baseline COHERE Study Group. AIDS. 28;22:
32 AIDS Diagnosis After Diagnosis of HIV Infection (%) Time to AIDS Diagnosis Almost half of the individuals over 5 years develop AIDS in less than 12 months 14.1% 85.9 % <2 (n=2354) 23.4% 76.6% 2 to 34 (n=18,893) 39.% 61.% 35 to 49 (n=16,679) <12 months (overall: 32.4%) >12 months (overall: 67.6%) 46.2% 53.8% >5 (n=6894) CDC. HIV Surveillance Report, 21.
33 Proportion Surviving Survival after AIDS Diagnosis 1.8 Survival after AIDS diagnosis is less if >5 years Age at Time of Diagnosis.6.4 < > Months After AIDS Diagnosis CDC. HIV Surveillance Report, 21.
34 ART Response by Age: % of people who experience an event 12 months after ART (p<.1) Age (ys) Virological response Discontinuation ART CD4> % 14.8% 86.7% 5.2% % 11.4% 8.6% 7.6% % 9.2% 76.3% 9.4% % 6.9% 75.2% 11.1% % 7.9% 73.9% 1.9% >6 61.8% 7.3% 74.7% 11.7% Total 53.7% 11.% 8.1% 8.1% AIDS event/death BETTER WORSE COHERE Study Group. AIDS. 28;22:
35 CHALLENGES IN MANAGEMENT OF CO-MORBIDITIES 73 yo male Smoker HIV 25 years CD4=483, RNA<2 Nadir CD4= 19 HTN DM Erectile dysfunction AMI and 3 vessel disease
36 Patients (%) VACS: Comorbidities in HIV infection 7 66% % 53% 45% Years <4 (n=8522) 4 to 49 (n=14,561) 5-59 (n=7225) >6 (n=3122) % Any Comorbidity 7% 17% 3% 6% 2% 12% 21% 4% 1% 11% 23% Hypertension Diabetes Vascular Disease 5% 7% 11% 16% Pulmonary Disease 5% 16% 17% 7% Liver Disease 6% 1% 2% 4% Renal Disease Goulet JL, et al. Clin Infect Dis. 27;45:
37 n= 9,583 AIDS events Non AIDS events OR Occurrence 16% 26% Cumulative mortality (6mo) 4.7% 13.4% 11.4
38 HANA: HIV Associated Non AIDS comorbitidies Cardiovascular disease Cognitive decline Cancer Osteoporosis Frailty Hypertension Diabetes Mellitus type 2 Hyperlipidemia Liver Failure Kidney Failure
39 Challenges: Cardiovascular Disease Cardiovascular Disease is more common in HIV infected patients when compared with uninfected controls and the risk increases with age
40 VACS Cohort AMI events per 1 person-years (p<.5) n = HIV infected HIV uninfected 4-49 ys ys Adjusted for co-morbidities, substance abuse, Framingham risks
41 HAND: 69% overall in the aviremic population ANI: Asymptomatic Neurocognitive Impairment MND: mild neurocognitive disorder HIV-D: HIV dementia 27% Nadir CD4 was associated with HAND
42 Malignancies in ART treated patients AIDS-related malignancies Kaposi sarcoma CNS lymphoma Non-AIDS defining malignancies Liver Larynx Anal Lung Nadir Low CD4 associated with Non- AIDS malignancies Mitsuyasu RT. Top HIV Med. 28;16: Engels EA, et al. Int J Cancer. 28;123: Patel P, et al. Ann Intern Med. 28;148:
43 Percent With Low BMD Osteopenia BMD is Lower in HIV-Infected Women > 4 Years of Age 3 27 HIV Infected 25 Control Femur neck and lumbar spine Femoral neck only Lumbar Spine only Arnsten JH, et al. Clin Infect Dis. 26;42:114-12
44 Normal aging Drug toxicity Lifestyle Immune Activation due to HIV Premature aging Comorbidities HANA Deeks S G, Phillips A N BMJ 29;338:bmj.a3172
45 Successful aging with HIV infection
46 Barriers and components of successful aging with HIV
47 Summary
48 What we know HIV population is aging Aging of the immune system is enhanced by HIV infection despite ART Aging individuals engage in HIV risk behaviors but providers fail to identify those and adhere to screening guidelines Comorbidities attributed to increasing age overlap with morbidity from HIV disease and are predicted by lower CD4 counts
49 New directions: Pathogenesis Understand the mechanisms that drive IA and aging in HIV infection (HIV reservoirs, viral coinfections, telomere length and telomerase activity, )
50 New directions - Diagnosis Expand testing to all at risk PrEP in the aging population
51 New directions - HIV care Early initiation of ART Strategies to improve immune recovery (intensification treatment, other immune therapies)
52 New directions - Comorbidities Guidelines for diagnosis and management of comorbidities Strategies to decrease inflammation and IA Anti-aging interventions Psychosocial management (HAND)
53 New directions Successful Aging Bio-behavioral interventions to promote successful aging
54 Deborah Jones Allan Rodriguez Anita Parmigiani Stephen Weiss Margaret Fischl Suresh Pallikkuth Michael Kolber Mario Stevenson Savita Pahwa OUR PATIENTS
C E L I A J. M A X W E L L, M. D
H I V / A I D S I N O L D E R I N D I V I D U A L S T H E G R A Y I N G O F T H E D I S E A S E E X T E N U A T I N G V S M I T I G A T I N G F A C T O R S C E L I A J. M A X W E L L, M. D., F A C P A
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationKaren Nieves-Lugo, PhD George Washington University
Effect of chronic pulmonary lung disease on the decline in physical function in HIV infected and uninfected veterans in the Veterans Aging Cohort Study Karen Nieves-Lugo, PhD George Washington University
More informationImpact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers
Impact of antiretroviral therapy on gut immunology and the HIV reservoir in elite controllers Connie J Kim (Abstract #185) Session: Building Better Therapeutics November 19, 2013 10:00am HIV Elite Controllers
More informationEndocrinopathy and Leukocyte Telomere Length in HIV+ Individuals in the CARMA Cohort
Endocrinopathy and Leukocyte Telomere Length in HIV+ Individuals in the CARMA Cohort Kristen M. Sokalski, Alice Mai, Jackson Chu, Hélène Côté, Evelyn J. Maan, Arianne Albert, Neora Pick, Deborah Money,
More information11/7/2012. HIV disease: Chronic Disease Patients are aging with their HIV disease on effective antiretroviral therapy (ART)
The Journey of HIV Infected Infected Patients Over 50: Implications for Nursing Care Objectives Julie Gumowski, RN, BSN Margaret Caplan, M.D. November 17, 2012 SAIC Frederick To discuss the prevalence
More informationAging and Cancer in HIV
Aging and Cancer in HIV Ronald Mitsuyasu, MD Professor of Medicine Director, UCLA Center for Clinical AIDS Research and Education Group Chairman, AIDS Malignancy Consortium (AMC) Age distribution of HIV-infected
More informationIntroduction to HIV and Aging
Introduction to HIV and Aging Sheree Starrett MD Medical Director - Rivington House June 27, 2008 Rivington House Objectives Know the demographics of aging and HIV Identify the similarities between aging
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationHIV and Common Comorbidities August 17, Michael MacVeigh, MD & Kristen Meyers, BS, CADC1
HIV and Common Comorbidities August 17, 2017 Michael MacVeigh, MD & Kristen Meyers, BS, CADC1 Learning Objectives 1) Confidently discuss basics of ARVs and common side effects of these medications 2) Understand
More informationOptimizing Health While Aging with HIV
Slide 1 Optimizing Health While Aging with HIV Todd T. Brown, MD, PhD Division of Endocrinology and Metabolism Johns Hopkins University Unfortunately, We are Not Slide 2 Immortal But How Do We Want to
More informationEmerging Considerations in neuroaids Internationally: Events in Acute and Early Infection
Emerging Considerations in neuroaids Internationally: Events in Acute and Early Infection Igor Grant, M.D. Director, HIV Neurobehavioral Research Center University of California, San Diego Although combination
More informationDr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Paddy Mallon Mater Misericordiae University Hospital, Dublin, Ireland 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationSituación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona
Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona Mortality per 1 patient-years HIV infection has changed from a fatal disease into a chronic condition This means long-term
More informationHIV, Multimorbidity, and Frailty: what s going on? (with apologies to Marvin Gaye)
HIV, Multimorbidity, and Frailty: what s going on? (with apologies to Marvin Gaye) Julian Falutz MD, FRCPC Director Comprehensive HIV Aging Initiative Chronic Viral Illness Service Senior Physician, Division
More informationOutline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose
Nutritional, Metabolic, and Gastrointestinal Complications in Pediatric HIV Infection Tracie L. Miller, MD Department of Pediatrics University of Miami, Miller School of Medicine I have no financial relationships
More informationESCMID Online Lecture Library. by author
Improving Patient Safety: the Neglected Impact of Age and Gender, ESCMID Postgraduate Technical Workshop HIV in men, women and elderly Juan Ambrosioni MD, PhD Content HIV in men and women: differences
More informationFrailty Predicts Recurrent but Not Single Falls 10 Years Later in HIV+ and HIV- Women
Frailty Predicts Recurrent but Not Single Falls 10 Years Later in HIV+ and HIV- Women Anjali Sharma, Deborah Gustafson, Donald R Hoover, Qiuhu Shi, Michael W Plankey, Phyllis C Tien, Kathleen Weber, Michael
More informationPrevalence of Comorbidities among HIV-positive patients in Taiwan
Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity
More informationHIV Infection in the Long-term Survivor (Older Patient)
HIV Infection in the Long-term Survivor (Older Patient) Howard Libman, MD Professor of Medicine, Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts Learning Objectives Define
More informationAlexander O. Pasternak, Mirte Scherpenisse, Ben Berkhout
Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4 + T-cell count at 96 weeks ART Alexander O.
More informationLGBT Aging: HIV Prevention and Primary Care for LGBT Older Adults
LGBT Aging: HIV Prevention and Primary Care for LGBT Older Adults Jonathan S. Appelbaum, MD, FACP, AAHIVS Associate Professor and Education Director, Internal Medicine Florida State University College
More informationThe Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV
The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider
More informationHIV & Aging: Evolving Clinical Considerations in the New Millennium
HIV & Aging: Evolving Clinical Considerations in the New Millennium Julian Falutz, MD, FRCP (C) Director, HIV Metabolic Clinic Immunodeficiency Treatment Centre Senior Physician Division of Geriatrics
More informationDispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin
Dispelling the myths: HIV, ageing and the changing causes of morbidity Caroline A Sabin Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), UCL, London, UK Disclosures I have
More informationPrimary Care for Persons Living with HIV
Primary Care for Persons Living with HIV Brian Montague, DO MS MPH Assistant Professor of Medicine Division of Infectious Diseases Warren Alpert School of Medicine Brown University Outline What constitutes
More informationSupplementary Material*
Supplementary Material* Park LS, Tate JP, Sigel K, Brown ST, Crothers K, Gibert C, et al. Association of Viral Suppression With Lower AIDS-Defining and Non AIDS-Defining Cancer Incidence in HIV-Infected
More informationHIV-Associated Inflammation: Do the drugs matter? Jun 15, 2018 Darrell H. S. Tan MD FRCPC PhD
HIV-Associated Inflammation: Do the drugs matter? Jun 15, 2018 Darrell H. S. Tan MD FRCPC PhD Faculty/Presenter Disclosure Faculty: Darrell H. S. Tan Relationships with financial sponsors / potential for
More informationDepression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention
The Alfred Hospital Depression in People Living with HIV/AIDS: Outcomes, Risks and Opportunities for Intervention Final Report August 2005 Chief Investigator Associate Professor Anne Mijch Infectious Diseases
More informationNational Council on Aging
National Council on Aging Engaging HIV+ Older Adults in Chronic Disease Self-Management Education July 19, 2016 Dr. Stephen E. Karpiak, ACRIA, Center on HIV and Aging Dr. Kate Lorig, Stanford Patient Education
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationClinical and Public Health Policy Implications of Findings that:
Clinical and Public Health Policy Implications of Findings that: Adherence to HIV Medications and Emotional/Physiological Coping with Stress are Independently Associated with Specific Five-Year Outcome
More informationUnderstanding contraceptive choices among a cohort of HIV-positive women
Understanding contraceptive choices among a cohort of HIV-positive women Malika Sharma, MD FRCPC with Blitz S, Walmsley S, Raboud J, Money D for the CTN 236 investigators January 13, 2014 Conflict of Interest
More informationPART IV! CLINICAL IMPLICATIONS
PART IV! CLINICAL IMPLICATIONS Background Biological link between HIV and aging paints a grim picture, however The benefits of ART strongly outweigh the risks associated with ongoing immune activation
More informationPhysical Function & Frailty in HIV
Physical Function & Frailty in HIV Kristine M. Erlandson, MD Assistant Professor University of Colorado Divisions of Infectious Diseases & Geriatric Medicine Research funding through the National Institutes
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationPIs are the real world answer for the chronic patient s management. Giovanni Guaraldi
PIs are the real world answer for the chronic patient s management Giovanni Guaraldi HIV MEDICATION TOXICITY Ageing with HIV: The clinical consequences AGEING Heart disease Kidney disease Liver disease
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationIncreased and accelerated age-related complications in HIV-infected patients
Increased and accelerated age-related complications in HIV-infected patients Giovanni Guaraldi Università di Modena THE CHANGING SPECTRUM OF HIV CARE Pre- HAART 1996 Early- HAART 2005 Late- HAART Opportunistic
More informationFactors Associated with Limitations in Daily Activity Among Older HIV+ Adults
Factors Associated with Limitations in Daily Activity Among Older HIV+ Adults KM Erlandson, K Wu, R Kalayjian, S Koletar, B Taiwo, FJ Palella Jr, K Tassiopoulos and the A5322 Team Background Growing burden
More informationClinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States
Clinical and Behavioral Characteristics of HIV-infected Young Adults in Care in the United States Linda Beer, PhD, Christine L. Mattson, PhD, Joseph Prejean, PhD, and Luke Shouse, MD 10 th International
More informationHIV AND LUNG HEALTH. Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital
HIV AND LUNG HEALTH Stephen Aston Infectious Diseases SpR Royal Liverpool University Hospital Introduction HIV infection exerts multiple effects on pulmonary immune responses: Generalised state of immune
More informationCase discussion: How do drugs/patients impact need and type of monitoring CASE 2
Case discussion: How do drugs/patients impact need and type of monitoring CASE 2 Marta Boffito Head of Clinical Trials, St. Stephen s Centre (SSAT) Consultant Physician, Chelsea and Westminster Foundation
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationImmune Activation: Impact on Outcomes Peter W. Hunt, MD. Associate Professor of Medicine University of California San Francisco
Immune Activation: Impact on Outcomes Peter W. Hunt, MD Associate Professor of Medicine University of California San Francisco 10y Decreased Life Expectancy in Older HIV+ Adults in Modern ART Era ~9y shorter
More informationHIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School
HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually
More informationAll biomarkers at higher level in HIV group
Supplemental Table S1: Summary of studies assessing mainly inflammatory biomarkers and their association with mortality and clinical endpoints in HIV infection First author, year, country Biomarkers measured
More informationOptimizing Treatment and Management of HIV/AIDS in Persons of Advanced Age
Optimizing Treatment and Management of HIV/AIDS in Persons of Advanced Age This activity is jointly provided by the University of Nebraska Medical Center and Practice Point Communications Supported by
More informationPrimary Care of the HIV-infected Adult: If I Can Do It, You Can Do It
Primary Care of the HIV-infected Adult: If I Can Do It, You Can Do It Howard Libman, MD Professor of Medicine, Emeritus Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationFor any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,
Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral
More informationPART VI! IMPLICATIONS FOR THERAPIES
PART VI! IMPLICATIONS FOR THERAPIES Background Current HIV and aging treatment advice: Start ART early and manage traditional risk factors for non-aids-related diseases aggressively Treatments to reverse
More informationAging and HIV: Living Life with Silver Hair
Georgia Southern University Digital Commons@Georgia Southern 6th Annual Rural HIV Research and Training Conference Sep 21st, 4:30 PM - 5:15 PM Aging and HIV: Living Life with Silver Hair Barbara J. Blake
More informationForget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?)
Forget me not: providing care for people living with HIV and dementia (What does the future hold for our elderly HIV patients?) Dr Simon Rackstraw FRCP Medical Director, Mildmay Hospital, London Consultant
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationDidactic Series. Non-Infectious Complications of HIV. Ankita Kadakia, MD UC San Diego, Owen Clinic November 8, 2018
Didactic Series Non-Infectious Complications of HIV Ankita Kadakia, MD UC San Diego, Owen Clinic November 8, 2018 1 Disclosures The following presenter have disclosed the following relationship with a
More informationChronic complications of HIV infection. An update Pablo Tebas, MD
Activity Code TM809 Chronic complications of HIV infection. An update 2014 Pablo Tebas, MD Learning Objectives Upon completion of this presentation, learners should be better able to: Identify and update
More informationMetabolic consequences of HIV-induced inflammation
Metabolic consequences of HIV-induced inflammation Jacqueline Capeau INSERM U938, Université Pierre et Marie Curie Faculté de Médecine, site Saint-Antoine, Hôpital Tenon, Paris, France 1. Pathogenesis
More informationInternational Forum on HIV and Rehabilitation Research
Neurocognitive screening and behavioural interventions for HIV-Associated Neurocognitive Disorders (HAND) International Forum on HIV and Rehabilitation Research Translating Research Evidence from the Canada-UK
More informationMortality in HIV Infection: Monitoring Quality Outcomes
Mortality in HIV Infection: Monitoring Quality Outcomes March 15, 2017 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious Diseases;
More informationThe Graying of HIV A Growing Population and a Chronic Disease. Dorcas Baker, RN, BSN, ACRN, MA Johns Hopkins AETC Site Director June 9, 2014
The Graying of HIV A Growing Population and a Chronic Disease Dorcas Baker, RN, BSN, ACRN, MA Johns Hopkins AETC Site Director June 9, 2014 Introduction The aging face of HIV/AIDS is attributed to two
More informationCase Presentation JF
Case Presentation History, P/E and relevant labs Male 85 yo, HIV Dx 1996 (CD4-550, HIV-RNA 5000) referred for care 1999 PHx: syphilis, 50 pack-yr cigarettes Meds: none MSM, single, unemployed, previous
More informationHIV Prevention Pearls
HIV Prevention Pearls Meghan Rothenberger, MD Assistant Professor Division of Infectious Diseases University of Minnesota Director, Youth and AIDS Projects October 27, 2017 Disclosure Information I have
More informationHIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression
HIV treatment interruptions are associated with heightened biomarkers of inflammation, coagulopathy and T-cell activation despite viral suppression Nicholas Musinguzi on behalf of Jose Castillo-Mancila,
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationCoagulation and Morbidity in Treated HIV Infection. Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University
Coagulation and Morbidity in Treated HIV Infection Michael M. Lederman, MD Scott R. Inkley Professor of Medicine Case Western Reserve University Although survival has improved, predicted life expectancy
More informationBHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over
BHIVA national clinical audit 2018: monitoring of adults with HIV aged 50 or over Data collection for BHIVA s 2018 national clinical audit is now open until 15 June. The aim is to assess adherence to standards
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationImportant Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers
Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,
More informationReceptive Anal Intercourse and HIV Infection
World Journal of AIDS, 2017, 7, 269-278 http://www.scirp.org/journal/wja ISSN Online: 2160-8822 ISSN Print: 2160-8814 Receptive Anal Intercourse and HIV Infection Gilbert R. Lavoie 1, John F. Fisher 2
More informationNew Insights in Pathogenesis Inflammation and Immune Activation
Activity Code TM809 New Insights in Pathogenesis Inflammation and Immune Activation Turner Overton, M.D. Associate Professor of Medicine University of Alabama at Birmingham Learning Objectives Upon completion
More informationFrailty and HIV: what is the evidence? Giovanni Guaraldi
Frailty and HIV: what is the evidence? Giovanni Guaraldi Disclosure Dr Guaraldi has served as a consultant for Bristol-Myers Squibb, Abbvie, Theratecnologies, Gilead Sciences, Inc, GlaxoSmithKline, Merck
More informationPreventive Care Guideline for Asymptomatic Elderly Patients Age 65 and Over
Preventive Care Guideline for Asymptomatic Elderly Patients Age 65 and Over 1. BMI - Documented in patients medical record on an annual basis up to age 74. Screen for obesity and offer counseling to encourage
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More information11/18/17. HIV and Aging. HIV and Frailty. Frailty. Mechanism of FuncEonal Decline: Role for Frailty in HIV and Aging
Mechanism of FuncEonal Decline: Role for Frailty in HIV and Aging Alan Landay, PhD Professor Department of Immunology/ Microbiology Rush University Medical Center Chicago, Illinois HIV and Aging The introduceon
More informationHow Do We Future Proof HIV Nursing
How Do We Future Proof HIV Nursing How Do We Future Proof HIV Nursing BHIVA monitoring guideline s Audit 123 services took part in the audit Data was collected on 8258 people living with HIV. All patients
More informationTop 10 Things to Know About the Older Patient With HIV Infection
Top 10 Things to Know About the Older Patient With HIV Infection Howard Libman, MD Professor of Medicine, Emeritus Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts Learning
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular
More informationFrailty and the Risk of Falls in HIV- Infected Older Adults in the ACTG A5322 Study
Frailty and the Risk of Falls in HIV- Infected Older Adults in the ACTG A5322 Study Katherine Tassiopoulos, Mona Abdo, Susan L. Koletar, Frank Palella, Babafemi Taiwo, and Kristine M. Erlandson for the
More informationInflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
PLoS MEDICINE Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection Lewis H. Kuller 1, Russell Tracy 2, Waldo Belloso 3, Stephane De Wit 4, Fraser Drummond 5, H. Clifford
More information50+ SHADES OF GREY, AGING WITH HIV
50+ SHADES OF GREY, AGING WITH HIV R E B E C C A G L A S S M A N, M D I N S T R U C T O R O F M E D I C I N E, H A R V A R D M E D I C A L S C H O O L MR. C 71 years old Diagnosed with HIV in 1998 at the
More information11/8/2016. The Challenge of HIV Treatment
You Mean I Have to Talk About...Sex? Trudy Larson, MD Professor and Director, School of Community Health Sciences Medical Director, Nevada AIDS Education and Training Center Nat l HIV/AIDS Strategy Goals
More informationHIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD
HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported
More informationGender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project,
Gender Disparities in Viral Suppression and Antiretroviral Therapy Use by Racial and Ethnic Group Medical Monitoring Project, 2009-2010 Linda Beer PhD, Christine L Mattson PhD, William Rodney Short MD,
More informationHIV, Aging, and Frailty: Cannonball?
HIV, Aging, and Frailty: Cannonball? Keri Althoff, PhD, MPH Assistant Professor Co-Director, NA-ACCORD Epidemiology/Biostatistics Core kalthoff@jhsph.edu Disclosures None Funding KN Althoff is supported
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationHIV A 2017 Update Bill Rooney MD SCOR Global Life
NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More informationDiastolic dysfunction predicts impaired aerobic capacity in older HIVinfected
Diastolic dysfunction predicts impaired aerobic capacity in older HIVinfected men Hillary McClintic Virginia Tech Carilion School of Medicine John Gottdiener, MD Kristina Crothers, MD Adeel A. Butt, MD
More informationKaposi Sarcoma Causes, Risk Factors, and Prevention
Kaposi Sarcoma Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn about the risk factors for Kaposi sarcoma.
More informationBone Mineral Density in a Cohort of Young Adult Women using Depoprovera and Tenofovir, Kampala, Uganda
Bone Mineral Density in a Cohort of Young Adult Women using Depoprovera and Tenofovir, Kampala, Uganda Flavia Matovu Kiweewa, Noah Kiwanuka, Delia Scholes, Esther Isingel, Mary Glenn Fowler, Clemensia
More informationHIV EPIDEMIOLOGY IN NEW YORK CITY
HIV EPIDEMIOLOGY IN NEW YORK CITY Ellen Weiss Wiewel, MHS HIV Epidemiology and Field Services Program New York City Department of Health and Mental Hygiene http://www.nyc.gov/html/doh/html/dires/hivepi.shtml
More informationThis work was supported by a grant from NIH: R21NR011131
This work was supported by a grant from NIH: R21NR011131 Deborah Jones, PhD Aman Sharma, MD Mahendra Kumar, PhD Drenna Waldrop-Valverde, PhD Stephen M. Weiss, PhD, MPH Ritu Nehra, PhD Szonja Vamos, MA
More informationHormonal Contraception Use and Non-AIDSdefining
Hormonal Contraception Use and Non-AIDSdefining Events Vlada Melekhin, MD, MPH January 10, 2012 Vanderbilt University Outline Background Methods Results Conclusions Limitations Future Directions Hormonal
More informationFuture challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study
Future challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study Guaraldi G 1, De Francesco D 2, Malagoli A 1, Theou O 3, Zona S 1, Carli F 1, Dolci G 1,
More information